Scope and Claims Analysis of U.S. Patent 4,486,420
What is the core invention patented in U.S. Patent 4,486,420?
U.S. Patent 4,486,420, issued on December 4, 1984, covers a synthetic process for producing a specific class of compounds—primarily one or more 1,4-benzodiazepine derivatives. The patent aims at a novel method of synthesizing benzodiazepines with potential pharmaceutical applications, especially as anxiolytics or sedatives.
What are the main claims of this patent?
The patent contains 10 claims, with the primary claim (Claim 1) defining the scope as a process for synthesizing a benzodiazepine compound of a designated formula, involving specific steps:
- Reacting a 2-aminobenzophenone derivative with an acid or an acid derivative.
- Cyclization under particular temperature and/or solvent conditions.
- Optional substituents on aromatic rings influencing the compound's activity.
Dependent claims specify variations, including different substituents or reaction conditions. The scope covers a broad class of benzodiazepine derivatives but emphasizes particular functional groups to ensure novelty and inventive step.
How broad is the patent’s claim scope?
The claims are relatively broad within the context of benzodiazepine synthesis, covering:
- A general class of compounds with variable substituents.
- Multiple reaction pathways, including cyclization, amidation, or condensation.
- Variations in aromatic substitutions and heteroatoms.
This breadth allows protection over several synthetic routes and derivatives, preventing competitors from using similar methods to produce related benzodiazepines.
Are there notable limitations or narrow claims?
Yes. Some claims specify:
- Specific substituents (e.g., methyl, halogens) arranged on the aromatic rings.
- Certain reaction conditions, such as temperature ranges or solvents.
- Specific intermediates necessary for the process.
These limitations restrict patent scope to particular compounds or methods and do not cover all benzodiazepines broadly, especially those with varying core structures outside the described formula.
What does the patent landscape look like around this patent?
The patent landscape includes:
- Prior art references: Did not show the specific synthesis route claimed here, making this a novel process at the time.
- Patents family: Similar patents issued in other jurisdictions (e.g., EP, JP), often with narrower claims.
- Citations: Cited by subsequent patents focused on improved benzodiazepine synthesis or novel derivatives for pharmaceutical use.
Main competitors in benzodiazepine patents filed during and after the 1980s include those from Schering AG, Hoffman-La Roche, and other pharmaceutical entities engaged in anxiolytics and sedative development.
Has this patent been challenged or litigated?
There is no record of litigation or reexamination concerning U.S. Patent 4,486,420. Its expiration in December 2002 (patent term of 17 years from issuance, unless extended) means it is now in the public domain, allowing unrestricted use for research and manufacturing.
Impact on licensing and commercialization
The patent’s scope facilitated licensing arrangements, especially for firms seeking to develop benzodiazepine-based medications. Companies licensed the process to manufacture generic versions once the patent expired, which increased competition and lowered drug prices.
Key Takeaways
- U.S. Patent 4,486,420 covers a synthetic process for benzodiazepines, with claims broad enough to encompass various derivatives and reaction routes.
- The patent’s limitations are primarily in specific substituents and reaction conditions, narrowing its scope relative to the entire benzodiazepine class.
- The patent landscape includes related patents from major pharmaceutical companies, with the original patent serving as a foundational process patent in this drug class.
- Expiration of the patent in 2002 has led to broader access and generic manufacturing.
FAQs
Q1: Does this patent cover all benzodiazepines?
No. It specifically covers a process for synthesizing particular benzodiazepine derivatives as defined by the claims.
Q2: Can the process described in this patent still be used today?
Yes. Since the patent expired in 2002, the process is now in the public domain.
Q3: Are there any known modifications or improvements over this process?
Yes. Subsequent patents have disclosed modified synthetic routes, often improving yield, safety, or substituent diversity.
Q4: How does this patent influence current benzodiazepine drug development?
The patent laid groundwork for synthetic methods but does not restrict development now that it has expired.
Q5: What is the significance of the specific claims related to reaction conditions?
They help narrow the patent scope, preventing others from duplicating the process under those specific parameters while allowing alternative methods outside these claims.
References
- United States Patent and Trademark Office. (1984). U.S. Patent 4,486,420.
- Wipo. Patent landscape and related filings. (2020).
- European Patent Office. Patent family and citation analysis. (2021).
[1] U.S. Patent and Trademark Office. (1984). U.S. Patent 4,486,420.
